Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Many online sellers of compounded GLP-1 receptor agonists may be misleading customers, a cross-sectional study suggested. Out ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

Biogen CEO Chris Viehbacher targets subcutaneous Leqembi release for Alzheimers treatment Biogens Chris Viehbacher outlines ...